Articles tagged with Amyotrophic Lateral Sclerosis
A Tohoku University study reveals that ALS-causing mutations converge on the dysregulation of UNC13A gene expression, which could lead to effective treatment strategies. The researchers identified two molecular mechanisms underlying this reduction, including mRNA destabilization and REST overexpression.
Answer ALS is launching a groundbreaking collaboration with Tulane University and the Pennington Biomedical Research Center to harness AI for ALS treatment discovery. The Louisiana AI Drug Development Infrastructure for ALS (LADDIA) will prioritize therapeutic targets using AI-driven insights from the Answer ALS' Neuromine Data Portal.
The FDA has granted orphan drug designation to a new gene therapy for Amyotrophic Lateral Sclerosis (ALS), a devastating disease with no current effective treatment. The therapy uses a viral vector expressing the secreted isoform of Klotho protein, showing promising results in preclinical studies.
Researchers at Cedars-Sinai created a lifelike model of motor neurons that die in patients with ALS, allowing them to detect differences between healthy and diseased cells. The study suggests that excessive glutamate signaling may be a contributing factor to the disease.
Researchers have created 'spinal cord-like' microtissues from stem cells to study ALS-linked neuroinflammation. These microtissues, derived from ALS patients and healthy donors, exhibit distinct inflammatory responses, enabling the testing of FDA-approved drugs for personalized treatment approaches.
Researchers at Uppsala University have created a model of human nerve tissue using 3D printing, enabling the testing of new drug treatments in a lab environment. This innovation allows for more precise medicine and could potentially lead to improved treatment options for ALS patients.
Researchers at UC Davis developed a brain-computer interface that translates neural activity into speech in real time. The technology allows individuals with ALS to communicate more naturally and inclusively, with 60% of synthesized words intelligible to listeners.
Researchers at Harvard University's Wyss Institute have successfully created human microglia cells in a dish, using induced pluripotent stem cells, within four days. This breakthrough enables new avenues for brain disease-focused research and potential therapeutic perspectives.
Researchers discover abnormal polyadenylation in ALS, affecting mRNA function and potentially leading to new therapeutic targets. The study suggests that correcting gene function through polyadenylation correction could prevent motor neuron dysfunction and death in ALS patients.
Old neurons exhibit unique defects resulting from molecular stress, making them more vulnerable to neurodegeneration. The study sheds light on the molecular mechanisms behind brain cell deterioration, which could lead to new therapies for preventing neurodegenerative diseases.
Researchers at University of Virginia Health System discovered that an immune molecule called STING drives the formation of harmful plaques and protein tangles associated with Alzheimer's. Blocking STING protected lab mice from mental decline, suggesting a promising treatment target for neurodegenerative diseases.
Researchers show that stress granules, previously implicated in neurodegenerative diseases, can actually suppress fibril formation and even reverse the effects of disease-causing mutations. This discovery offers new insights into the development of potential treatments for neurodegenerative diseases.
A novel therapy developed by Columbia University scientist Neil Shneider has shown unprecedented functional recovery in patients with a rare form of ALS caused by a genetic mutation in the FUS gene. After six months of treatment, patients experienced up to an 83% decrease in neurofilament light, a biomarker of nerve damage.
Researchers at Stockholm University and UK DRI have identified a common disease signature across all ALS-causing mutations in motor neurons, revealing early mitochondrial dysfunction. This discovery opens up new avenues for early treatment methods, targeting the energy factories of nerve cells before other signs of disease appear.
Scientists have developed a sugar-coated nanotherapy that effectively traps misfolded proteins, neutralizing their toxic effects on neurons. The treatment significantly boosts the survival of lab-grown human neurons under stress from disease-causing proteins.
A protein link between brain diseases and leaky blood vessels reveals that endothelial cell dysfunction plays a crucial role in the progression of neurodegenerative diseases. The study found that reduced TDP-43 levels lead to gaps in blood vessel walls, allowing toxic molecules to enter the brain.
Researchers at Thomas Jefferson University used computational biology to analyze blood samples from people with and without ALS, discovering different combinations of small non-coding RNAs associated with disease progression and survival times.
A team of researchers from Goethe University and Kiel University has discovered a way to prevent the formation of harmful protein aggregates in cultured cells. The study found that linking TDP-43 with SUMO prevents its aggregation, suggesting a potential new approach for treating ALS and other neurodegenerative diseases.
Researchers found that ATP regulates protein condensation and cytoplasm viscosity, preventing harmful protein aggregates. Boosting ATP production decreases viscosity, dispersing existing and preventing future protein aggregations.
A dual-principal investigator research group led by Dartmouth and the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital will test the effectiveness of video as a communication tool during patient visits for people living with Amyotrophic Lateral Sclerosis (ALS) and their caregivers.
A new Northwestern University study finds that NU-9 improves neuron health in animal models of Alzheimer's disease by addressing the underlying mechanisms of misfolded proteins. The drug reduces protein buildup and prevents inflammation, showing potential for treating neurodegenerative diseases.
A machine-learning algorithm named catGRANULE 2.0 ROBOT identifies molecular targets for further researches and therapies in neurodegenerative diseases. The algorithm analyzes protein-RNA interaction to predict potential harm and identify early pathological signals.
The ALL ALS Consortium has recruited over 300 participants across two studies, ASSESS and PREVENT, aiming to disrupt traditional ALS research by making data and samples available worldwide. The consortium seeks to discover new drug targets and approaches for effective treatments.
Researchers from UConn School of Medicine reveal a novel pathway in cellular dysfunction contributing to neurodegenerative diseases like Alzheimer's and ALS. They discovered that endothelial cells, the inner lining of blood vessels, play a critical role in neurodegeneration by disrupting the blood-brain barrier's protection.
Researchers investigated the effects of electroacupuncture on gut microbiota and metabolomics in ALS patients, finding a reduction in Eisenbergiella abundance and improvements in Lachnospiraceae levels. The study suggests that this treatment may be beneficial for patients with ALS.
Researchers found that p-tau proteins in blood are elevated in both Alzheimer's and ALS patients, making them less specific for Alzheimer's diagnosis. However, they also show promise as potential biomarkers for early detection of ALS or monitoring disease progression.
Scientists repurposed the drug edaravone as an imaging probe to detect oxidative stress in brain tissue using PET scans. This technique can help diagnose neurological conditions such as ALS and Alzheimer's disease earlier, when treatment is more effective.
Dr. Guy Rouleau, a renowned geneticist and neurologist, has founded the world's first academic institution committed to open science principles. The Neuro institute aims to transform how brain disease research is conducted worldwide by promoting data sharing and collaboration.
A new blood test may help identify and monitor Amyotrophic Lateral Sclerosis (ALS), according to a recent study published in Neurology. The test uses neurofilament light chain proteins to accurately diagnose ALS, with an accuracy rate of over 80%.
The HEALEY ALS Platform Trial has evaluated four treatment regimens for Amyotrophic Lateral Sclerosis (ALS), a fatal neurodegenerative disease, using a common research setup. The trial showed promising trends in other outcome measures and biomarkers, informing the design of future phase 3 trials.
A recent study from IR Sant Pau investigates the peripheral immune system's role in amyotrophic lateral sclerosis (ALS) at the single-cell level. The research found altered NK cell subpopulations associated with ALS progression, suggesting a potential target for new therapies.
A Michigan Medicine-led study suggests that living in disadvantaged communities may decrease the length of time a person can survive with amyotrophic lateral sclerosis (ALS) by up to 37%. The study found that patients from more resourced areas tended to live longer, possibly due to better access to care and reduced caregiver burnout. T...
The project's recordings help improve voice recognition tools by providing diverse speech patterns to train artificial intelligence models. Microsoft has seen significant improvements in recognizing non-standard English speech, with accuracy gains ranging from 18% to 60%, depending on the speaker's disability.
Organoids derived from patient iPSCs accurately replicate ALS phenotypes, supporting drug development. However, challenges remain in utilizing these models for comprehensive ALS research and other neurodegenerative diseases.
A recent study suggests that tiny antenna-like structures on cells called primary cilia could be a potential therapeutic target for Amyotrophic Lateral Sclerosis (ALS). Researchers have identified mutations in the C21orf2 gene, which impair primary cilia formation and structure, leading to motor neuron death.
A new method has been developed to create motor neurons from stem cells taken directly from ALS patients, allowing for fast and individualized drug testing. The cultured ALS motor neurons had increased susceptibility to cell death, underscoring the utility of this system to identify potential drugs.
Recent studies suggest a connection between the protein G3BP1 and ALS disease, with toxic dipeptide repeats impairing normal cellular functions. The findings provide valuable insights into the underlying mechanisms of neurodegenerative disorders.
The partnership integrates Answer ALS’s Neuromine Data Portal with the AD Data Initiative's AD Workbench, providing a unified platform for data sharing and analysis. This collaboration enables integrative analysis of ALS and Alzheimer’s data, streamlining efforts and enhancing research impact.
The largest ALS patient-based iPSC and bio data repository was released by Answer ALS, offering an unprecedented resource for researchers studying ALS. The repository encompasses biological and clinical data from nearly 1,000 ALS patients and provides a comprehensive model for disease research and drug discovery.
A recent study has identified 51 amyotrophic lateral sclerosis (ALS)-associated mutations in mitochondrial DNA that could help diagnose the disease. The mutations, which include 13 that increase the risk of ALS and 38 protective ones, were found to be significantly associated with an increased or decreased risk of developing the disease.
Researchers have unveiled a complex interplay between liver X and thyroid hormone receptors that regulates critical brain functions and protects against neurodegeneration. LXRs play a crucial role in regulating thyroid hormone function in the brain, while both receptors are essential for normal brain development and maintenance.
Researchers have identified specific human endogenous retrovirus sequences associated with increased risk of neurodegenerative diseases, including multiple sclerosis and amyotrophic lateral sclerosis. The study suggests that these viral elements contribute to disease susceptibility by influencing brain function.
A new study found that toxic SOD1 protein trimers interact with various proteins in different tissues, contributing to cellular dysfunction and degeneration in ALS. Septin-7 is identified as a potential therapeutic target, potentially slowing or disrupting ALS progression.
Scientists have developed new therapies that selectively remove aggregated tau proteins associated with Alzheimer's disease in mice. The approach utilises TRIM21 to target tau aggregates, leaving healthy tau intact, and demonstrates potential for other brain disorders driven by protein aggregation.
A highly accurate diagnostic blood test has been developed for amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that affects neurons in the brain and spinal cord. The test requires only a simple blood draw and can distinguish between ALS patients and healthy controls with an overall accuracy of up to 98%.
New research reveals that downregulating the enzyme EGLN2 can protect motor neurons and mitigate ALS symptoms in animal models. This discovery brings hope to understanding how to slow or prevent this devastating disease.
A clinical trial led by UC San Francisco aims to develop new therapies for progressive supranuclear palsy, with a focus on reducing time to find effective treatments and increasing diverse participant enrollment. The five-year grant could lead to the first effective drugs for this incurable neurodegenerative disorder.
Researchers have identified two proteins, PARP1 and histone H1.2, that interact with an ALS-causing mutant FUS protein, leading to pathological changes. Inhibiting these proteins may be a possible therapeutic target for familial ALS cases caused by mutations in the FUS gene.
Researchers discovered that Huntington's disease protein aggregates cause breaks in the nuclear envelope, leading to DNA damage and misregulation of neuronal genes. The study suggests a common mechanism for neurodegenerative diseases involving nuclear aggregate-induced ruptures.
Researchers developed a new brain-computer interface that translates brain signals into speech with up to 97% accuracy, enabling a man with amyotrophic lateral sclerosis (ALS) to communicate with friends and family. The system was tested in real-time conversations with continuous updates, achieving high word accuracy rates.
Researchers have identified a metal deficiency in SOD1 protein associated with motor neurone disease using native ambient mass spectrometry imaging. This breakthrough could lead to new insights and treatments for the disease, which affects around 5,000 people in the UK.
A University of Michigan-led study found that higher levels of metals in blood and urine are associated with a greater risk for ALS and shorter survival. Occupational exposure to metals was also linked to increased metal levels, emphasizing the need for accounting for environmental factors when evaluating overall exposure risk.
A new immune cell therapy has been shown to delay ALS onset and extend survival in mice, as well as reduce inflammation in an individual with the disease. In a phase I clinical trial, the therapy is now set to be tested on humans.
A new study published in Neurology suggests that moderate levels of physical activity and fitness may be linked to a reduced risk of amyotrophic lateral sclerosis (ALS) later in life. Male participants who engaged in higher levels of physical activity had a lower risk of developing ALS compared to those with lower activity levels.
A study by TUM researchers discovered four subtypes of Amyotrophic Lateral Sclerosis (ALS) with different molecular processes, including sex differences. The findings suggest repurposing an approved cancer drug targeting the MAPK pathway as a promising therapeutic approach for ALS.
Researchers have developed a blood test that can detect rare forms of dementia, such as frontotemporal dementia (FTD) and progressive supranuclear palsy (PSP), as well as amyotrophic lateral sclerosis (ALS). The test uses biomarkers, including tau and TDP-43 proteins, to identify underlying pathology.
A new study reveals how the FUS protein behaves in ALS and FTD, mirroring what is observed in human diseases where protein aggregates spread and contribute to neurodegeneration. The research supports the broader hypothesis that many neurodegenerative diseases involve prion-like mechanisms.
Dr. Jeetain Mittal's NIH grant will support multiscale computational models investigating phase separation in biology, particularly heterochromatin formation and its role in neurodegenerative diseases. The research aims to elucidate the molecular origins of phase separation using innovative models and methods.
A new study published in PLOS One found that ALS patients treated by neurologists received interventions endorsed by the American Academy of Neurology, including non-invasive ventilation and feeding tubes. Disparities were found in treatment among Black and disadvantaged patients, highlighting the need for equitable care.
Researchers at Ben-Gurion University of the Negev and international colleagues found that augmenting MIF protein levels delays motor function decline, modulates critical pathways, and extends lifespan in a SOD1 mouse model of ALS. Diminished MIF levels are also observed in familial and sporadic ALS cases.